23:41 , Aug 3, 2018 |  BioCentury  |  Emerging Company Profile

Compass’ range

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies. Traditional approaches to antibody discovery use hybridoma fusions in animals,...
23:17 , May 24, 2018 |  BC Innovations  |  Product R&D

Bias-less bispecifics

Taking a leaf from the small molecule playbook, cancer play Merus N.V. is bringing unbiased screening to the bispecifics space. The biotech is betting the approach can discover bispecific antibodies with novel activity against known...
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
00:56 , Aug 29, 2017 |  BC Extra  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
00:21 , May 20, 2016 |  BC Extra  |  Financial News

Merus inches up after IPO

Bispecific antibody developer Merus B.V. (NASDAQ:MRUS) rose $0.04 to $10.04 in its first day of trading Thursday after it raised $55 million through the sale of 5.5 million shares at $10 in an IPO. Earlier...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

MCLA-117: Phase I/II started

Merus began an open-label, dose-escalation, international Phase I/II trial to evaluate MCLA-117 in up to 50 patients. The trial will enroll patients with relapsed or refractory AML and those aged >65 years with newly diagnosed...
07:00 , Aug 28, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) CD3; C-type lectin domain family 12 member A (CLEC12A; CLL1) Studies in patient...
07:00 , May 26, 2014 |  BioCentury  |  Finance

Europe's Iceberg 2014: Premier League teams

Competing in biotech's Premier League requires deep pockets, long term planning and the risk appetite to pursue novel technologies or targets that don't always pan out. BioCentury's 12th annual European Iceberg survey reveals that for...
07:00 , Oct 14, 2013 |  BioCentury  |  Finance

Betting on Biclonics

Betting on Biclonics Merus B.V. attracted a trio of pharma investors to its €31 million ($41.9 million) extension of a series B round, which it hopes will be enough to move its lead bispecific cancer antibodies...
00:34 , Oct 4, 2013 |  BC Extra  |  Financial News

Merus secures EUR 31 million in B round extension

Merus B.V. (Utrecht, the Netherlands) secured EUR 31 million ($41.9 million) in a tranched extension of a series B round, bringing the total secured in the round to EUR 47.6 million ($64.4 million). The company...